Enhanced Human Cytomegalovirus GB Polypeptide for Specialized Applications

The inventive concept adapts the human cytomegalovirus GB polypeptide for high-security bioresearch facilities, disaster relief efforts, extreme weather conditions, high-containment laboratories, and remote or isolated research stations, providing enhanced stability, thermal stability, and binding properties.

The original patent disclosed engineered mutants of human cytomegalovirus glycoprotein B (gB) protein with improved stability and immunogenicity. However, these mutants may not be suitable for specialized applications requiring high-security, extreme weather conditions, or remote research settings. The new inventive concept addresses these limitations by introducing novel mutations and adaptations for these niche environments.

The enhanced human cytomegalovirus GB polypeptide comprises at least two amino acid mutations, including at least one engineered disulfide mutation and at least one additional mutation. These mutations provide improved stability in prefusion form, thermal stability, and binding properties to prefusion-specific antibodies. The inventive concept can be implemented in various forms, including systems for high-security bioresearch facilities, methods for disaster relief efforts, and systems for extreme weather conditions, high-containment laboratories, and remote or isolated research stations.

The new claims introduce novel mutations and adaptations that are non-obvious and provide significant advantages over the original patent. The combination of engineered disulfide mutations and additional mutations for enhanced stability, thermal stability, and binding properties is a key inventive step.

Alternative embodiments may include different combinations of mutations, varying the number and type of engineered disulfide mutations and additional mutations. Variations may also include different forms of the inventive concept, such as expression systems, vaccine formulations, or diagnostic tools.

The enhanced human cytomegalovirus GB polypeptide has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the development of vaccines and diagnostic tools for high-security, disaster relief, and extreme weather condition applications.